Compare · CBUS vs EVGN
CBUS vs EVGN
Side-by-side comparison of Cibus Inc. (CBUS) and Evogene Ltd (EVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBUS and EVGN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- CBUS is the larger of the two at $136.6M, about 17.9x EVGN ($7.6M).
- Over the past year, CBUS is up 6.5% and EVGN is down 51.3% - CBUS leads by 57.9 points.
- EVGN has hit the wire 4 times in the past 4 weeks while CBUS has been quiet.
- Both have 4 recent analyst ratings on file.
- Company
- Cibus Inc.
- Evogene Ltd
- Price
- $1.79-1.65%
- $0.63+6.81%
- Market cap
- $136.6M
- $7.6M
- 1M return
- +36.64%
- +8.17%
- 1Y return
- +6.55%
- -51.35%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 4
- Recent ratings
- 4
- 4
Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Latest CBUS
- SEC Form S-8 filed by Cibus Inc.
- SEC Form S-8 filed by Cibus Inc.
- Europe Recognizes Nature-Based Plant Improvement, Opening a New Pathway for Cibus
- CEO Wichner Craig was granted 894,309 shares (SEC Form 4)
- Cibus Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
- Cibus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Finn Mark Terrence
- SEC Form 4 filed by Director Moretti August J
- SEC Form 4 filed by Director Riggs Rory B
Latest EVGN
- SEC Form 424B5 filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities
- Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery
- Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization
- SEC Form 6-K filed by Evogene Ltd
- SEC Form 6-K filed by Evogene Ltd
- Evogene to Present Its Pharma Division Achievements at the BIO International Convention
- Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica
- SEC Form 424B3 filed by Evogene Ltd